11,333 Shares in Enovis Co. (NYSE:ENOV) Purchased by KLP Kapitalforvaltning AS

KLP Kapitalforvaltning AS acquired a new stake in shares of Enovis Co. ( NYSE:ENOV – Free Report ) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 11,333 shares of the company’s stock, valued at approximately $497,000.

Several other institutional investors have also modified their holdings of ENOV. Sei Investments Co. raised its holdings in Enovis by 51.



0% during the 4th quarter. Sei Investments Co. now owns 453,241 shares of the company’s stock valued at $19,888,000 after buying an additional 153,006 shares during the period.

Xponance Inc. raised its stake in shares of Enovis by 7.8% in the fourth quarter.

Xponance Inc. now owns 6,380 shares of the company’s stock valued at $280,000 after acquiring an additional 462 shares during the period. Boston Partners lifted its holdings in shares of Enovis by 27.

1% in the 4th quarter. Boston Partners now owns 1,048,532 shares of the company’s stock worth $46,034,000 after acquiring an additional 223,816 shares during the last quarter. Royce & Associates LP grew its holdings in Enovis by 2.

8% during the 4th quarter. Royce & Associates LP now owns 2,470,576 shares of the company’s stock valued at $108,409,000 after purchasing an additional 66,891 shares during the last quarter. Finally, Envestnet Portfolio Solutions Inc.

raised its position in Enovis by 19.5% in the 4th quarter. Envestnet Portfolio Solutions Inc.

now owns 15,433 shares of the company’s stock worth $677,000 after purchasing an additional 2,518 shares during the period. 98.45% of the stock is owned by institutional investors.

Analyst Ratings Changes Separately, Needham & Company LLC restated a “buy” rating and set a $64.00 target price on shares of Enovis in a research report on Wednesday. Enovis Trading Down 8.

8 % ENOV stock opened at $33.74 on Friday. Enovis Co.

has a 12 month low of $33.73 and a 12 month high of $62.79.

The firm’s 50-day moving average is $41.21 and its 200 day moving average is $43.16.

The company has a market capitalization of $1.92 billion, a PE ratio of -15.41 and a beta of 2.

05. The company has a debt-to-equity ratio of 0.40, a current ratio of 2.

27 and a quick ratio of 1.12. Enovis ( NYSE:ENOV – Get Free Report ) last issued its earnings results on Wednesday, February 26th.

The company reported $0.98 EPS for the quarter, topping analysts’ consensus estimates of $0.92 by $0.

06. The business had revenue of $560.98 million for the quarter, compared to analyst estimates of $555.

14 million. Enovis had a negative net margin of 5.95% and a positive return on equity of 4.

39%. On average, research analysts anticipate that Enovis Co. will post 2.

79 EPS for the current year. Enovis Profile ( Free Report ) Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy.

The company operates through Prevention and Recovery, and Reconstructive segments. Read More Want to see what other hedge funds are holding ENOV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Enovis Co.

( NYSE:ENOV – Free Report ). Receive News & Ratings for Enovis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enovis and related companies with MarketBeat.com's FREE daily email newsletter .

.